INTRODUCTION {#s1}
============

Streptococcus pneumoniae (pneumococcus) is a common Gram-positive inhabitant of the human nasopharynx, which is its natural reservoir. There it may reside as a commensal bacterium along with other microorganisms identified on the respiratory epithelium. Such asymptomatic carriage is highest during the first year of life, with rates up to 79%, and progressively declines with age to rates of \<10% in adults ([@B1][@B2][@B3]). Nasopharyngeal (NP) colonization is a prerequisite for transmission of pneumococci to other individuals and for developing pneumococcal disease. S. pneumoniae is a leading cause of a wide range of infections, including otitis media, community-acquired pneumonia, sepsis, and meningitis ([@B4], [@B5]).

There is widespread evidence that natural colonization is an immunizing event that leads to humoral immunity to capsular polysaccharide (PS) antigens ([@B6]). These PS are an important class of virulence factors, of which \>90 different serotypes exist ([@B7]). PS-specific humoral immunity is highly protective, as is evidenced by the effectiveness of currently licensed pneumococcal conjugate vaccines (PCV) that may contain 10 to 13 different serotypes ([@B8][@B9][@B15]). The drawback of PS-based immunity is that it is highly serotype specific and that pneumococci expressing nonvaccine serotype PS can still colonize the PCV-vaccinated host, calling for novel PS-independent vaccines ([@B11][@B12][@B15]).

Natural as well as experimental colonization also induces humoral and cell-based immune responses to pneumococcal proteins, a class of more conserved antigens ([@B16][@B17][@B22]). Anti-protein antibody responses were shown to protect against invasive pneumococcal disease ([@B23][@B24][@B26]), whereas CD4^+^ T-cell-based immunity, in particular that mediated by interleukin-17A (IL-17A)-producing Th17 cells, plays an important role in the prevention of pneumococcal recolonization ([@B18], [@B25], [@B27], [@B28]) and experimental pneumonia in mice ([@B29]). Recently, Th17 cells mediating responses to pneumococcal protein antigens, being detectable only at low frequencies in peripheral blood mononuclear cells (PBMCs), have also been implied in the protection against colonization in humans ([@B30]). Th17 responses are involved in the recruitment and activation of neutrophils, monocytes, and macrophages, which results in quick clearance of opsonized pneumococci by phagocytosis ([@B18], [@B27], [@B28]).

Unlike antibody responses, CD4^+^ T cells do not recognize whole antigens or conformational epitopes. Instead, they clonally recognize intracellularly degraded fragments of antigens that are presented at the cell surface of antigen-presenting cells (APC) in the peptide-binding groove of self-major histocompatibility complex (MHC) class II molecules. These MHC class II molecules are highly polymorphic. Main human MHC class II molecules implied in CD4^+^ T-cell immunity are human leukocyte antigen (HLA)-DR molecules. These are transmembrane dimers consisting of an alpha and beta chain whose membrane-distal domains together form a peptide-binding groove. Of the functional loci encoding HLA-DR beta chains, the HLA-DRB1 locus is by far the most polymorphic, leading to many HLA-DRB1 alleles in the population that have slightly different binding motifs impacting which peptides become bound and presented to T cells ([@B31][@B32][@B34]). The low frequencies of antigen-specific CD4^+^ T cells in PBMCs and this dependence on the presence of MHC class II-matched APC in T-cell assays dictate that large numbers of an individual's PBMCs are required to screen arrays of pneumococcal proteins for CD4^+^ T-cell recognition. Therefore, as opposed to serology ([@B35][@B36][@B38]), the S. pneumoniae antigenome recognized by human CD4^+^ T cells has remained largely unknown, with the exception of a few proteins ([@B18], [@B39][@B40][@B44]). While complicating T-cell studies, MHC binding rules can also help to predict which protein sequences likely become MHC class II molecules presented to T cells, thereby facilitating a selectivity approach in T-cell immunogenicity screening ([@B43], [@B45], [@B46]).

In the current study, we evaluated proof of principle for a reverse immunology platform to *in silico* predict the T-cell immunogenicity for a semilarge panel of pneumococcal proteins based on HLA-DRB1 binding motifs. Predicted protein regions were validated by *in vitro* assessment of human peripheral T-cell responses to synthetic peptides and whole proteins. We found proof that hitherto unknown specificities and genuine HLA-DR-restricted pneumococcal CD4^+^ T-cell epitopes can be elucidated by bioinformatics. This provides a peptide-based PBMC-saving strategy to study cell-mediated immune mechanisms to S. pneumoniae.

RESULTS {#s2}
=======

Pneumococcal proteins show significant potential for T-cell immunogenicity. {#s2.1}
---------------------------------------------------------------------------

A nonsaturating primary list of 100 pneumococcal proteins, likely targeted by the adaptive immune system, was selected from the TIGR4 proteome of \>2,000 open reading frames for bioinformatics analysis, mainly based on earlier evidence for B- or T-cell recognition or on their protective potential as a vaccine candidate ([Table 1](#T1){ref-type="table"}) ([@B35], [@B36], [@B41], [@B43], [@B44], [@B47][@B48][@B49]). CD4^+^ T cells do not preferentially target surface proteins; therefore, selected proteins of various subcellular localizations, comprising cell wall, cell membrane, cytoplasmic proteins, secreted proteins, and proteins with unknown localization, were included ([Table 1](#T1){ref-type="table"}). The immunogenic potential of the 100 selected proteins was determined *in silico* based on the binding of potential epitopes to common HLA-DRB1 types and is expressed as an EpiMatrix protein score. Twelve out of 100 proteins showed an EpiMatrix protein score of \>20, indicating a significant potential for T-cell immunogenicity. Potential cross-reactivity of frames against the human genome, as determined by a Janus protein score of \>3, was limited to a single protein CglC (SP_2051) ([Table 1](#T1){ref-type="table"}). The 12 proteins with an EpiMatrix protein score above 20, together with eight known (pre)clinical vaccine candidates with various EpiMatrix protein scores, were selected for further analyses ([Table 2](#T2){ref-type="table"}). Ranking of the selected proteins next to common proteins with known immunogenicity revealed that all vaccine candidate proteins had EpiMatrix protein scores of \<20, which was lower than those of, e.g., tetanus toxin and influenza hemagglutinin ([Fig. 1](#F1){ref-type="fig"}). Five out of eight (pre)clinical vaccine candidates even had an EpiMatrix protein score lower than the average (−2.6) for all 100 proteins ([Fig. 1](#F1){ref-type="fig"}). However, such a low score does not exclude the immunogenic potential of dedicated protein regions within a protein. The EpiMatrix system identified 264 putative T-cell immunogenic clusters within the 20 selected proteins. Potential cross-reactivity with human peptides was indicated for 60 clusters with Janus cluster scores above 2.0 (data not shown). Characteristics and sequences of the 2 to 5 potentially most immunogenic regions per protein, selected for peptide synthesis and further *in vitro* immunogenicity analysis, are shown in [Table 2](#T2){ref-type="table"}.

###### 

Characteristics and immunogenicity scores of 100 selected pneumococcal proteins

  Gene name   Strain   Protein designation   Length (amino acids)   Protein name                                                      Localization[^*a*^](#T1F1){ref-type="table-fn"}   No. of EpiMatrix hits   EpiMatrix protein score   Janus protein score   Reference
  ----------- -------- --------------------- ---------------------- ----------------------------------------------------------------- ------------------------------------------------- ----------------------- ------------------------- --------------------- --------------------------------
  SP_0546     TIGR4    BlpZ                  77                     BlpZ protein, fusion                                              Cell membrane                                     96                      260.54                    0.75                  [@B48]
  SP_2051     TIGR4    CglC                  108                    Competence protein                                                Unknown                                           86                      115.79                    4.78                  [@B36]
  SP_1839     TIGR4                          583                    Putative ABC transporter ATP-binding protein exp8                 Cell membrane                                     480                     102.54                    2.39                  [@B44]
  SP_2048     TIGR4                          153                    Conserved hypothetical protein                                    Cell membrane                                     113                     100.28                    2.42                  [@B36]
  SP_1434     TIGR4                          586                    ABC transporter, ATP-binding protein                              Mitochondral membrane                             456                     94.88                     1.51                  [@B44]
  SP_0008     TIGR4                          122                    Uncharacterized protein                                           Cell membrane                                     89                      89.29                     1.25                  [@B36]
  SP_1241     TIGR4                          721                    Amino acid ABC transporter, amino acid-binding protein            Cell membrane                                     466                     53.86                     1.33                  [@B35], [@B36]
  SP_0468     TIGR4                          283                    Putative sortase                                                  Cell membrane                                     165                     43.68                     2.45                  [@B36]
  SP_2204     TIGR4    RplI                  150                    Ribosomal protein L9                                              Ribosome                                          78                      30.1                      1.49                  [@B36]
  SP_0667     TIGR4                          328                    Pneumococcal surface protein, putative                            Cell membrane                                     166                     22.25                     0.56                  [@B35], [@B36]
  SP_2201     TIGR4    CbpD                  448                    Choline-binding protein D                                         Cell wall                                         222                     21.17                     0.52                  [@B35], [@B36]
  SP_2136     TIGR4    PcpA                  621                    Choline-binding protein A                                         Cell wall                                         319                     21.16                     1.03                  [@B35], [@B36], [@B44], [@B47]
  SP_0348     TIGR4    CpsC                  230                    Capsular polysaccharide biosynthesis protein                      Cell membrane                                     114                     18.68                     2.68                  [@B36]
  SP_1759     TIGR4    SecA-2                790                    Preprotein translocase, SecA subunit                              Cell membrane, cytoplasm                          395                     18.25                     1.09                  [@B36]
  SP_0770     TIGR4                          513                    ABC transporter, ATP-binding protein                              Unknown                                           254                     18.14                     1.98                  [@B36]
  SP_1732     TIGR4    StkP                  659                    Serine/threonine protein kinase                                   Cell membrane                                     331                     17.48                     2.34                  [@B35], [@B36], [@B40]
  SP_1072     TIGR4    DnaG                  586                    DNA primase                                                       Primosome                                         284                     16.55                     1.13                  [@B44]
  SP_0466     TIGR4                          279                    Sortase, putative                                                 Cell membrane                                     133                     16.05                     1.54                  [@B36]
  SP_2239     TIGR4    HtrA                  393                    Serine protease                                                   Unknown                                           191                     15.27                     1.08                  [@B35], [@B36]
  SP_0529     TIGR4    BlpC                  453                    BlpC ABC transporter                                              Mitochondral membrane                             222                     14.24                     1.52                  [@B35], [@B36]
  SP_0369     TIGR4    PonA                  719                    Penicillin-binding protein 1A                                     Secreted                                          346                     14.19                     1.8                   [@B36]
  SP_0378     TIGR4    CbpJ                  328                    Choline-binding protein J                                         Cell wall                                         158                     13.86                     0.24                  [@B36]
  SP_1650     TIGR4    PsaA                  309                    Manganese ABC transporter substrate-binding lipoprotein           Cell membrane                                     145                     12.35                     1.46                  [@B35], [@B36]
  SP_0222     TIGR4    RpsN                  89                     Ribosomal protein S14                                             Ribosome                                          40                      11.6                      0.88                  [@B36]
  SP_1676     TIGR4                          305                    *N*-Acetylneuraminate lyase, putative                             Unknown                                           147                     11.3                      0.78                  [@B36]
  SP_1954     TIGR4                          467                    Serine protease, subtilase family                                 Unknown                                           214                     11.09                     0.98                  [@B36]
  SP_0197     TIGR4                          416                    Dihydrofolate synthetase, putative                                Unknown                                           200                     10.34                     1.62                  [@B36]
  SP_2128     TIGR4                          285                    Transketolase, N-terminal subunit                                 Unknown                                           136                     9.64                      1.01                  [@B36]
  SP_2021     TIGR4                          469                    Glycosyl hydrolase                                                Unknown                                           213                     7.58                      0.97                  [@B36]
  SP_0377     TIGR4    CbpC                  340                    Choline-binding protein C                                         Cell wall                                         155                     7.38                      0.39                  [@B35], [@B36]
  SP_1980     TIGR4    Cbf1                  308                    Cmp-binding factor 1                                              Unknown                                           140                     6.07                      1.9                   [@B36]
  SP_0609     TIGR4                          254                    Amino acid ABC transporter, amino acid-binding protein            Unknown                                           111                     4.71                      1.04                  [@B36]
  SP_0613     TIGR4    RnJ                   553                    Ribonuclease J                                                    Cytoplasm                                         244                     4.22                      1.31                  [@B36]
  SP_1891     TIGR4    AmiA                  659                    Oligopeptide ABC transporter                                      Cell membrane                                     296                     3.8                       1.34                  [@B35], [@B36]
  SP_2099     TIGR4    Pbp1B                 821                    Penicillin-binding protein 1B                                     Cell membrane                                     361                     2.41                      1.79                  [@B36]
  SP_1527     TIGR4    AliB                  652                    Oligopeptide ABC transporter                                      Cell membrane                                     289                     1.56                      1.46                  [@B35], [@B36]
  SP_0390     TIGR4    CbpG                  285                    Choline-binding protein G                                         Cell wall                                         119                     1.52                      0.71                  [@B36]
  SP_0688     TIGR4    MurD                  450                    UDP-*N*-acetylmuramoylalanine--[d]{.smallcaps}-glutamate ligase   Cytoplasm                                         193                     −0.52                     1.12                  [@B36]
  SP_2194     TIGR4                          810                    ATP-dependent Clp protease, ATP-binding subunit                   Unknown                                           348                     −0.83                     1.19                  [@B36]
  SP_1687     TIGR4    NanB                  697                    Neuraminidase B                                                   Unknown                                           295                     −1.17                     1                     [@B35], [@B36]
  SP_1553     TIGR4                          623                    ABC transporter, ATP-binding protein                              Cytoplasm                                         270                     −1.42                     2.11                  [@B44]
  SP_1573     TIGR4    LytC                  490                    Lysozyme                                                          Cell wall                                         206                     −2.59                     0.7                   [@B35], [@B36]
  SP_2039     TIGR4                          207                    Conserved hypothetical protein                                    Unknown                                           85                      −4.93                     0.89                  [@B36]
  SP_2141     TIGR4                          626                    Glycosyl hydrolase-related protein                                Unknown                                           255                     −5.03                     1.05                  [@B36]
  SP_1227     TIGR4                          234                    DNA-binding response regulator                                    Unknown                                           94                      −5.9                      1.63                  [@B36]
  SP_0509     TIGR4    HsdM                  487                    Type I restriction-modification system, M subunit                 Unknown                                           198                     −6.52                     1.55                  [@B36]
  SP_0251     TIGR4                          812                    Formate acetyltransferase, putative                               Cytoplasm                                         331                     −7.39                     1.34                  [@B36]
  SP_1221     TIGR4                          1,084                  Type II restriction endonuclease                                  Unknown                                           438                     −7.58                     1.57                  [@B36]
  SP_1124     TIGR4    GlgA                  477                    Glycogen synthase                                                 Unknown                                           197                     −7.99                     0.65                  [@B36]
  SP_0330     TIGR4    RegR                  333                    Sugar-binding transcriptional regulator                           Unknown                                           133                     −8.8                      0.92                  [@B36]
  SP_1999     TIGR4    CcpA                  336                    Catabolite control protein A                                      Unknown                                           133                     −9.07                     1.08                  [@B36]
  SP_1923     TIGR4    Ply                   471                    Pneumolysin                                                       Secreted, cell membrane                           188                     −9.4                      0.8                   [@B36], [@B47], [@B49]
  SP_0981     TIGR4    PrsA                  313                    Foldase protein                                                   Cell membrane                                     122                     −9.91                     2.07                  [@B35], [@B36]
  SP_0295     TIGR4    RpsI                  130                    Ribosomal protein S9                                              Ribosome                                          49                      −9.95                     1.02                  [@B36]
  SP_2216     TIGR4    PcsB                  392                    Secreted 45-kDa protein Usp45                                     Secreted                                          152                     −10.97                    2.43                  [@B35], [@B36], [@B44]
  SP_0071     TIGR4    ZmpC                  1,856                  Immunoglobulin A1 protease, zinc metallose C                      Secreted, cell wall                               721                     −12.03                    1.25                  [@B35], [@B36]
  SP_1032     TIGR4    PiaA                  341                    Iron compound ABC transporter                                     Periplasm                                         128                     −12.47                    1.16                  [@B35], [@B36]
  SP_0148     TIGR4                          276                    ABC transporter, substrate-binding protein                        Unknown                                           102                     −12.68                    1.12                  [@B36]
  SP_1283     TIGR4                          107                                                                                      Cell membrane                                     40                      −13.02                    0.9                   [@B36]
  SP_0212     TIGR4    RplB                  277                    Ribosomal protein L2                                              Ribosome                                          106                     −13.12                    1.28                  [@B36]
  SP_0749     TIGR4    LivJ                  386                    Branched-chain amino acid ABC transporter                         Periplasm                                         148                     −13.59                    1.28                  [@B35], [@B36]
  SP_0785     TIGR4                          399                    Conserved hypothetical protein                                    Cell membrane                                     152                     −17.42                    1.36                  [@B35], [@B36]
  SP_1154     TIGR4    ZmpA                  2,004                  IgA1 protease                                                     Secreted, cell wall                               739                     −18.31                    1.4                   [@B35], [@B36]
  SP_0664     TIGR4    ZmpB                  1,906                  Zinc metallose B (putative)                                       Secreted, cell wall                               684                     −18.87                    1.02                  [@B35], [@B36]
  SP_0930     TIGR4    CbpE                  627                    Choline binding protein E                                         Cell wall                                         223                     −18.91                    1.41                  [@B35], [@B36]
  SP_0117     TIGR4    PspA                  744                    Pneumococcal surface protein A                                    Cell wall                                         272                     −19.17                    0.95                  [@B35], [@B36], [@B43]
  SP_1287     TIGR4    Ffh                   523                    Signal recognition particle protein                               Cytoplasm                                         187                     −19.59                    1.15                  [@B36]
  SP_1175     TIGR4                          802                    Conserved domain protein                                          Unknown                                           282                     −20.34                    1.4                   [@B35], [@B36]
  SP_0057     TIGR4    StrH                  1,312                  Beta-*N*-acetylhexosaminidase                                     Secreted, cell wall                               473                     −20.55                    0.96                  [@B35], [@B36]
  SP_0943     TIGR4    Gid                   444                    Gid protein                                                       Cytoplasm                                         162                     −20.85                    0.52                  [@B36]
  SP_1330     TIGR4    NanE                  233                    *N*-Acetylmannosamine-6-P epimerase, putative                     Unknown                                           80                      −21.28                    1.28                  [@B36]
  SP_1804     TIGR4                          202                    General stress protein 24, putative                               Unknown                                           67                      −21.42                    1.64                  [@B36]
  SP_1522     TIGR4                          205                    Conserved domain protein                                          Unknown                                           70                      −21.87                    1.23                  [@B36]
  SP_0641     TIGR4                          2,140                  Serine protease                                                   Cell membrane, cell wall                          744                     −21.91                    0.88                  [@B35], [@B36], [@B44]
  SPR0561     R6       PrtA                  2,144                  Cell wall-associated proteinase                                   Cell membrane, cell wall                          727                     −24.14                    0.84                  [@B35], [@B36]
  SP_1888     TIGR4    AmiE                  355                    Oligopeptide ABC transporter, ATP-binding protein                 Cell membrane                                     116                     −26.07                    1.74                  [@B36]
  SP_2092     TIGR4    GalU                  299                    UTP-glucose-1-phosphate uridylyltransferase                       Unknown                                           98                      −26.17                    0.77                  [@B36]
  SP_0463     TIGR4                          665                    Cell wall surface anchor family protein                           Cell membrane, cell wall, secreted                217                     −26.65                    1.82                  [@B36]
  SP_1661     TIGR4    DivIVA                262                    Cell division protein                                             Cytoplasm                                         87                      −27.6                     0.97                  [@B36]
  SP_2190     TIGR4    CbpA                  693                    PspC/choline-binding protein A                                    Secreted                                          227                     −28.02                    0.45                  [@B35], [@B36]
  SP_0368     TIGR4    GH101                 1,767                  Cell wall surface anchor family protein                           Secreted, cell wall                               589                     −28.22                    1.14                  [@B35], [@B36]
  SP_1735     TIGR4    Fmt                   311                    Methionyl-tRNA formyltransferase                                  Unknown                                           99                      −28.56                    0.61                  [@B36]
  SP_1991     TIGR4                          257                    Putative hydrolase                                                Unknown                                           81                      −29.27                    1.07                  [@B36]
  SP_0082     TIGR4                          857                    Cell wall surface anchor protein                                  Secreted, cell wall                               273                     −31.05                    1.25                  [@B35], [@B36]
  SP_0069     TIGR4    CbpI                  211                    Choline-binding protein I                                         Cell wall                                         61                      −35.15                    0.25                  [@B36]
  SP_0239     TIGR4                          445                    Conserved hypothetical protein                                    Unknown                                           130                     −37.2                     1.3                   [@B36]
  SP_0498     TIGR4                          1,659                  Endo-β-*N*-acetylglucosaminidase, putative                        Secreted, cell wall                               486                     −38.88                    1.3                   [@B35], [@B36]
  SP_0648     TIGR4    BgaA                  2,233                  β-Galactosidase                                                   Secreted, cell wall                               633                     −39.14                    0.98                  [@B35], [@B36]
  SP_0519     TIGR4    DnaJ                  378                    DnaJ protein                                                      Cytoplasm                                         107                     −39.26                    1.85                  [@B36]
  SP_1174     TIGR4                          819                    Conserved domain protein                                          Unknown                                           228                     −39.36                    1.41                  [@B35], [@B36]
  SP_1429     TIGR4                          428                    Peptidase, U28 family                                             Unknown                                           123                     −39.75                    0.72                  [@B36]
  SPR0907     R6       PhtD                  853                    Pneumococcal histidine triad protein D                            Cell membrane                                     235                     −41.55                    1.59                  [@B35], [@B36], [@B47]
  SP_1478     TIGR4                          280                    Oxidoreductase, aldo/ketoreductase family                         Unknown                                           74                      −42.22                    1.11                  [@B36]
  SP_2108     TIGR4    MalX                  423                    Maltose ABC transporter                                           Cell membrane                                     113                     −43.4                     1.07                  [@B35], [@B36]
  SP_1664     TIGR4    SepF                  179                    Cell division protein                                             Cytoplasm                                         47                      −43.76                    0.4                   [@B36]
  SP_0107     TIGR4    LysM                  195                    Domain protein                                                    Unknown                                           46                      −50.7                     0.93                  [@B35], [@B36]
  SP_1937     TIGR4    LytA                  318                    Autolysin                                                         Secreted                                          69                      −54.36                    0.9                   [@B35], [@B36]
  SP_1374     TIGR4    AroC                  388                    Chorismate synthetase                                             Unknown                                           85                      −56.28                    0.64                  [@B36]
  SP_1992     TIGR4                          221                    Cell wall surface anchor family protein                           Cell membrane                                     41                      −64.4                     0.95                  [@B36]
  SP_1772     TIGR4                          4,776                  Cell wall surface anchor family protein                           Cell membrane                                     303                     −96.41                    1.11                  [@B36]

Subcellular localization based on UniprotKB database.

###### 

Characteristics of immunogenic regions in the selected proteins and vaccine candidates

  Ranking in EpiMatrix protein score[^*a*^](#T2F1){ref-type="table-fn"}   Gene name   Protein name/designation                                 Cluster address[^*b*^](#T2F2){ref-type="table-fn"}   Cluster sequence[^*c*^](#T2F3){ref-type="table-fn"}   Synthesized peptides (location)   Hydrophobicity[^*d*^](#T2F4){ref-type="table-fn"}   EpiMatrix hits[^*e*^](#T2F5){ref-type="table-fn"}^,^[^*f*^](#T2F6){ref-type="table-fn"}   EpiMatrix cluster score[^*f*^](#T2F6){ref-type="table-fn"}^,^[^*g*^](#T2F7){ref-type="table-fn"}   Janus cluster score
  ----------------------------------------------------------------------- ----------- -------------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------- --------------------------------- --------------------------------------------------- ----------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- ---------------------
  1                                                                       SP_0546     BlpZ                                                     30--57                                               FNV**FVLTFVSAVVFNFLNSMLALMA**IFI                      30--47, 40--57                    2.09                                                39                                                                                        76.27                                                                                              0.34
                                                                                                                                               58--77                                               GAG**YVVGFWLLILNENQRA**N                              60--77                            0.27                                                20                                                                                        36.19                                                                                              2.25
                                                                                                                                               10--32                                               SKT**LDRLTPYILVLASDTIA**FNV                           10--27, 15--32                    0.59                                                14                                                                                        21.17                                                                                              0.31
                                                                                                                                               1--18                                                M**YKHLFFLDSKTLDR**LTP                                1--18                             −0.27                                               11                                                                                        18.34                                                                                              0.55
                                                                                                                                               46--60                                               LNS**MLALMAIFI**GAG                                   46--60                            1.82                                                6                                                                                         11.24                                                                                              0.27
  2                                                                       SP_2051     CglC                                                     20--46                                               EM**LVVLLIISVLFLLFVPNLTKQK**EAV                       20--37, 29--46                    1.52                                                43                                                                                        80.29                                                                                              7.64
                                                                                                                                               1--24                                                **MKKMMTFLKKAKVKAFTLVEM**LVV                          1--18, 7--24                      0.7                                                 22                                                                                        36.63                                                                                              2.22
  3                                                                       SP_1839     Putative ABC transporter ATP-binding protein exp8        164--194                                             LTA**LVLLFLPLIFLLVNLYRKKSVKIIE**KTR                   164--181, 172--189, 177--194      1                                                   56                                                                                        106.56                                                                                             5.06
                                                                                                                                               11--43                                               LKR**LMSYLKPYGLLTFLALSFLLATTVIKS**VIP                 6--23, 19--36, 25--42             1.08                                                43                                                                                        71.09                                                                                              5.8
                                                                                                                                               74--97                                               LQT**VVQYVGNLLFARVSYSIV**RDI                          74--91, 80--97                    0.74                                                29                                                                                        48                                                                                                 1.28
                                                                                                                                               136--162                                             FSG**ILSSFISAVFIFLTTLYTMLV**LDF                       136--153, 154--162                1.78                                                26                                                                                        44.08                                                                                              0.97
                                                                                                                                               243--267                                             ALD**ALFLRPAMSLLKLLGYAVL**MAY                         243--260, 250--267                1.32                                                25                                                                                        40.49                                                                                              1.3
  4                                                                       SP_2048     Conserved hypothetical protein                           23--47                                               LLA**LIVISGGLLLFQAMSQLLI**SEV                         23--40, 30--47                    1.88                                                27                                                                                        53.31                                                                                              3.38
                                                                                                                                               8--34                                                QSK**SHKVKAFTLLESLLALIVISG**GLL                       8--25, 17--34                     0.88                                                27                                                                                        52.34                                                                                              4.56
                                                                                                                                               129--145                                             LVR**FHFQFQKGLER**EFI                                 129--145                          −0.18                                               11                                                                                        21.26                                                                                              0.09
                                                                                                                                               108--127                                             GRG**YQPMVYGLKSVRIT**EDN                              109--126                          −0.76                                               12                                                                                        18.91                                                                                              0.42
                                                                                                                                               98--112                                              SDD**FRKTNARGR**GYQ                                   98--112                           −2.03                                               7                                                                                         12.73                                                                                              0.14
  5                                                                       SP_1434     ABC transporter, ATP-binding protein                     259--288                                             IIP**IVYFMTSLASAKVILLELIMILFL**SGV                    260--277, 271--288                2.05                                                36                                                                                        59.16                                                                                              0.93
                                                                                      15--40                                                   DKK**YLGVLAIIFSAISAALTVYG**YYL                       15--32, 23--40                                        1.06                              32                                                  55.21                                                                                     2.91                                                                                               
                                                                                                                                               35--61                                               VYG**YYLIYKFLDKLIINSNLSGAE**SIA                       35--52, 44--61                    0.5                                                 28                                                                                        50.67                                                                                              2.68
                                                                                                                                               151--174                                             ALG**FIVSIRVGIILLALTIIG**GLI                          151--168, 157--174                2.4                                                 23                                                                                        39.93                                                                                              4.34
                                                                                                                                               513--538                                             QKA**FKNLMKDKTVIMIAHRLSTI**KDL                        513--530, 521--538                −0.16                                               21                                                                                        34.1                                                                                               0.96
  6                                                                       SP_0008     Uncharacterized protein                                  30--57                                               RNR**FMGGVLILIMLLFILPTFNLAQ**SYQ                      33--50, 40--57                    0.94                                                29                                                                                        45.06                                                                                              2.13
                                                                                                                                               2--17                                                SKN**IVQLNNSFIQ**NEY                                  2--17                             −0.72                                               16                                                                                        33.86                                                                                              0.56
                                                                                                                                               47--68                                               LPT**FNLAQSYQQLLQRRQQ**LAD                            47--64, 51--68                    −0.73                                               17                                                                                        32.05                                                                                              1.28
                                                                                                                                               96--116                                              AAK**YTRAKYYYSKSREKV**YTI                             97--114                           −1.12                                               11                                                                                        15.5                                                                                               0.45
  7                                                                       SP_1241     Amino acid ABC transporter, amino acid-binding protein   694--720                                             MYA**ILAIFYLVIITLLTRLAKRLE**KRI                       694--711, 703--720                1.14                                                36                                                                                        66.02                                                                                              3.45
                                                                                      508--531                                                 QNN**YKQLLSGLGITLALALIS**FAI                         508--525, 514--531                                    0.93                              23                                                  47.43                                                                                     3.12                                                                                               
                                                                                                                                               1--23                                                **MKKKFLAFLLILFPIFSLGI**AKA                           1--18, 6--23                      1.42                                                26                                                                                        44.64                                                                                              3.52
                                                                                                                                               532--558                                             AIV**IGIIFGMFSVSPYKSLRVISE**IFV                       533--550, 541--558                1.51                                                24                                                                                        36.64                                                                                              0.88
                                                                                                                                               277--293                                             FAP**FVFQNSSNQYT**GID                                 277--293                          −0.25                                               15                                                                                        32.08                                                                                              1
  8                                                                       SP_0468     Putative sortase                                         259--283                                             RGL**VVLAFLGILFVLWKLARLLRG**K                         259--276, 266--283                1.33                                                38                                                                                        67.95                                                                                              4.29
                                                                                                                                               3--26                                                RTK**LRALLGYLLMLVACLIPI**YCF                          3--20, 9--26                      1.45                                                23                                                                                        44.98                                                                                              5.1
                                                                                                                                               91--114                                              PDA**VYGYLSIPSLEIMEPVYL**GAD                          92--109                           0.38                                                13                                                                                        19.93                                                                                              0.77
                                                                                                                                               49--73                                               TEM**YQEQQNHSLAYNQRLASQN**RIV                         49--66, 56--73                    −1.21                                               12                                                                                        16.48                                                                                              0.71
                                                                                                                                               40--55                                               HAT**FVKSMTTEMY**QEQ                                  40--55                            −0.79                                               9                                                                                         16.34                                                                                              0
  9                                                                       SP_2204     RplI                                                     22--42                                               PTG**YAQNFLIKKNLAKEA**TAQ                             23--40                            −0.56                                               18                                                                                        31.83                                                                                              3.11
                                                                                                                                               130--150                                             DVP**VKIYQDITSVINLRVKEG**                             133--150                          −0.02                                               17                                                                                        27.31                                                                                              1.24
                                                                                                                                               101--121                                             AEE**LQKQFGIKIDKRHIQ**VQA                             102--119                          −0.78                                               12                                                                                        19.1                                                                                               0.25
                                                                                                                                               1--20                                                MK**VIFLADVKGKGKKGE**IKE                              1--18                             −0.37                                               8                                                                                         11.6                                                                                               2.13
                                                                                                                                               89--103                                              GRT**FGSITNKKI**AEE                                   89--103                           −0.81                                               6                                                                                         11.45                                                                                              1.43
  10                                                                      SP_0667     Pneumococcal surface protein, putative                   293--319                                             AKS**YNSLFHMSKKRMYRQLTSDFD**KFS                       293--310, 302--319                −1.02                                               20                                                                                        33                                                                                                 0.71
                                                                                      154--174                                                 KNA**WQGAYYLKSNGKMAQ**GEW                            156--173                                              −1.17                             16                                                  28.72                                                                                     0.38                                                                                               
                                                                                                                                               73--97                                               KGA**FKAKQSTAIQINTSSATTS**GWV                         73--90, 80--97                    −0.27                                               15                                                                                        22.93                                                                                              0.2
                                                                                                                                               1--19                                                M**NKRLFSKMSLVTLPI**LAL                               1--18, 2--19                      0.86                                                15                                                                                        22                                                                                                 0.44
                                                                                                                                               265--282                                             DGV**WKEVQASTASSS**NDS                                265--282                          −0.86                                               12                                                                                        21.6                                                                                               1.58
  11                                                                      SP_2201     CbpD                                                     10--30                                               GTS**YYLKMSVKKLVPFLV**VGL                             11--28                            0.84                                                21                                                                                        42.72                                                                                              1.64
                                                                                                                                               351--375                                             TVG**WKKINGSWYHFKSNGSKST**GWL                         351--368, 358--375                −0.83                                               16                                                                                        29.66                                                                                              0.56
                                                                                                                                               237--260                                             YTA**YNGSYRYVQLEAVNKNPL**GNS                          237--254, 243--260                −0.82                                               18                                                                                        27.21                                                                                              0.24
                                                                                                                                               75--94                                               CTS**FVAFRLSNVNGFEI**PAA                              75--92                            0.69                                                12                                                                                        21.91                                                                                              0.92
                                                                                                                                               313--334                                             YTA**YNGSRRYIQLEGVTSS**QNY                            313--330, 317--334                −1                                                  12                                                                                        19.78                                                                                              0.79
  12                                                                      SP_2136     PcpA                                                     180--205                                             TSA**FSFSQKLKKLTFSSSSKLEL**ISH                        180--197, 188--205                −0.14                                               27                                                                                        47.43                                                                                              2.11
                                                                                                                                               220--242                                             PKS**VKTLGSNLFRLTTSLKH**VDV                           220--237, 225--242                −0.1                                                19                                                                                        35.03                                                                                              2.19
                                                                                                                                               285--307                                             LAS**YSFNKNSYLKKLELNEG**LEK                           285--302, 290--307                −0.8                                                19                                                                                        30.72                                                                                              1.7
                                                                                                                                               205--228                                             HEA**FANLSNLEKLTLPKSVKT**LGS                          205--223, 211--228                −0.21                                               18                                                                                        27.09                                                                                              1.14
                                                                                                                                               420--440                                             SEH**IKDVLKSNLSTSNDI**IVE                             422--439                          −0.3                                                15                                                                                        23.65                                                                                              2.8
  16                                                                      SP_1732     StkP[^*h*^](#T2F8){ref-type="table-fn"}                  342--365                                             KMR**YLILLASLVLVAASLIWI**LSR                          342--359, 348--365                1.6                                                 39                                                                                        80.67                                                                                              7.24
                                                                                                                                               262--288                                             VSE**MYVDLSSSLSYNRRNESKLIF**DET                       262--279, 271--288                −0.61                                               24                                                                                        37.72                                                                                              1.25
                                                                                                                                               111--135                                             EEA**VRIMGQILLAMRLAHTRGI**VHR                         111--128, 118--135                0.24                                                22                                                                                        36.66                                                                                              1.82
                                                                                                                                               243--266                                             LEN**VIIKATAKKLTNRYRSVS**EMY                          243--260, 249--266                −0.41                                               16                                                                                        24.29                                                                                              1.44
                                                                                                                                               219--236                                             TIA**LQHFQKPLPSVI**AEN                                219--236                          0.08                                                13                                                                                        22.85                                                                                              3.54
  17                                                                      SP_1072     DnaG[^*h*^](#T2F8){ref-type="table-fn"}                  381--403                                             QIE**FLEKIAPLIVQEKSIAA**QNS                           381--398, 386--403                0.11                                                19                                                                                        31.04                                                                                              0.85
                                                                                                                                               16--37                                               IVE**VIGDVISLQKAGRNYL**GLC                            16--33, 20--37                    0.73                                                16                                                                                        26.88                                                                                              1.18
                                                                                                                                               446--468                                             TMP**VTKQLSAIMRAEAHLLY**RMM                           446--463, 451--468                0.21                                                15                                                                                        25.87                                                                                              2.73
                                                                                                                                               289--309                                             REH**VEHLKRLTKKLVLVY**DGD                             289--306, 292--309                −0.75                                               14                                                                                        24.52                                                                                              2.64
                                                                                                                                               569--586                                             DTA**LEELERLISQKRRME**                                569--586                          −1.13                                               14                                                                                        23.52                                                                                              1.71
  23                                                                      SP_1650     PsaA[^*h*^](#T2F8){ref-type="table-fn"}                  1--22                                                **MKKLGTLLVLFLSAIILVA**CAS                            1--18, 5--22                      1.92                                                36                                                                                        67.66                                                                                              3.53
                                                                                                                                               138--161                                             PHA**WLNLENGIIFAKNIAKQL**SAK                          138--155, 144--161                −0.05                                               21                                                                                        35.46                                                                                              0.38
                                                                                                                                               30--52                                               GQK**LKVVATNSIIADITKNI**AGD                           30--47, 35--52                    0.15                                                13                                                                                        19.05                                                                                              1.38
                                                                                                                                               205--222                                             EGA**FKYFSKAYGVPS**AYI                                205--222                          0.03                                                10                                                                                        18.83                                                                                              0.5
                                                                                                                                               289--309                                             GDS**YYSMMKYNLDKIAEG**LAK                             289--306, 292--309                −0.6                                                11                                                                                        17.32                                                                                              0.09
  52                                                                      SP_1923     Ply[^*h*^](#T2F8){ref-type="table-fn"}                   40--61                                               PDE**FVVIERKKRSLSTNTS**DIS                            40--57, 44--61                    −0.75                                               21                                                                                        35.85                                                                                              1.86
                                                                                                                                               405--425                                             TAH**FTTSIPLKGNVRNLS**VKI                             405--422, 408--425                0.07                                                14                                                                                        25.56                                                                                              1.35
                                                                                                                                               231--253                                             ERP**LVYISSVAYGRQVYLKL**ETT                           231--248, 236--253                −0.09                                               17                                                                                        25.45                                                                                              0.29
                                                                                                                                               244--259                                             RQV**YLKLETTSKS**DEV                                  244--259                          −0.91                                               9                                                                                         19.2                                                                                               0.89
                                                                                                                                               6--28                                                VND**FILAMNYDKKKLLTHQG**ESI                           6--23, 11--28                     −0.35                                               12                                                                                        17.19                                                                                              0.5
                                                                                                                                               173--191                                             GNS**LDIDFNSVHSGEK**QIQ                               174--191                          −0.79                                               8                                                                                         10.98                                                                                              0.44
  55                                                                      SP_2216     PcsB[^*h*^](#T2F8){ref-type="table-fn"}                  1--20                                                **MKKKILASLLLSTVMVS**QVA                              1--18                             1.07                                                25                                                                                        43.59                                                                                              8.04
                                                                                                                                               114--135                                             NGA**VTSYINTIVNSKSITE**AIS                            117--134                          0.23                                                15                                                                                        24.26                                                                                              0.47
                                                                                                                                               140--161                                             MSE**IVSANNKMLEQQKADK**KAI                            140--157, 144--161                −0.7                                                13                                                                                        22.53                                                                                              0.62
                                                                                                                                               55--76                                               VDQ**IQEQVSAIQAEQSNLQ**AEN                            55--72, 59--76                    −0.77                                               12                                                                                        21.29                                                                                              1.58
                                                                                                                                               246--268                                             QQS**VLASANTNLTAQVQAVS**ESA                           246--263, 251--268                0                                                   13                                                                                        18.55                                                                                              0.23
  66                                                                      SP_0117     PspA[^*h*^](#T2F8){ref-type="table-fn"}                  673--690                                             NGS**WYYLNANGSMAT**GWV                                673--690                          −0.27                                               21                                                                                        41.33                                                                                              0.1
                                                                                                                                               1--19                                                MNK**KKMILTSLASVAI**LGA                               2--19                             0.84                                                18                                                                                        31.98                                                                                              2.11
                                                                                                                                               593--610                                             SDK**WYYVNSNGAMAT**GWL                                593--610                          −0.47                                               13                                                                                        23.92                                                                                              0
                                                                                                                                               225--242                                             QHQ**VDNLKKLLAGAD**PDD                                225--242                          −1.02                                               9                                                                                         15.59                                                                                              1.44
                                                                                                                                               185--204                                             KYD**YATLKVALAKKEVE**AKE                              185--204                          −0.68                                               8                                                                                         10.91                                                                                              1.13
  74                                                                      SP_0641     Serine protease[^*h*^](#T2F8){ref-type="table-fn"}       378--399                                             GEK**YWQAIRALRKAGIPMV**VAT                            378--395, 382--399                0.05                                                18                                                                                        35.22                                                                                              1.33
                                                                                                                                               1085--1103                                           REH**FIRGILNSKSNDA**KGI                               1085--1102                        −0.76                                               17                                                                                        33.69                                                                                              0.44
                                                                                                                                               204--221                                             EEA**IDYLKSINAPFG**KNF                                204--221                          −0.41                                               16                                                                                        32.28                                                                                              0.38
                                                                                                                                               138--158                                             EKA**IKELSSLKNTKVLYT**YDR                             139--156                          −0.85                                               16                                                                                        29.18                                                                                              3.06
                                                                                                                                               913--936                                             MEA**LNSNGKKINFQPSLSMPL**MGF                          913--930, 919--936                −0.11                                               17                                                                                        28.98                                                                                              0.38
  92                                                                      SPR_0907    PhtD[^*h*^](#T2F8){ref-type="table-fn"}                  805--830                                             DSS**IRQNAVETLTGLKSSLLLGT**KDN                        805--822, 813--830                −0.38                                               18                                                                                        28.39                                                                                              2.89
                                                                                                                                               606--624                                             AEA**IYNRVKAAKKVPL**DRM                               607--624                          −0.44                                               14                                                                                        27.87                                                                                              0.86
                                                                                                                                               1--22                                                **MKINKKYLAGSVAVLALSV**CSY                            1--18, 5--22                      0.8                                                 15                                                                                        22.03                                                                                              4.13
                                                                                                                                               834--853                                             SAE**VDSLLALLKESQPTPI**Q                              835--852                          −0.01                                               13                                                                                        20.54                                                                                              3.46
                                                                                                                                               618--641                                             KVP**LDRMPYNLQYTVEVKNGS**LII                          618--635, 624--641                −0.11                                               11                                                                                        14.42                                                                                              0.25

Ranking number within the list of 100 pneumococcal proteins in [Table 1](#T1){ref-type="table"} based on EpiMatrix protein score.

The cluster address is the location of the peptide within the protein sequence; clusters are ranked according to their EpiMatrix cluster score.

The identified core peptides (in boldface) are depicted within N- and C-terminal flanks (not in boldface), which are required for further analysis in immunoassays.

Hydrophobicity scores of 2 and above are predictive of difficulty synthesizing peptides.

EpiMatrix hits is the number of Z scores above 1.64.

EpiMatrix cluster score derives from the number of hits normalized for the length of the cluster and thus is the excess or shortfall in predicted aggregate immunogenicity to a random peptide standard.

Without flanks.

Preclinical or clinical vaccine candidate.

![EpiMatrix immunogenicity scale of the 20 selected pneumococcal proteins compared to well-known proteins. The top 12 most immunogenic proteins (with EpiMatrix protein scores of \>20) were selected, together with 8 (pre)clinical vaccine candidates with various EpiMatrix protein scores. Their EpiMatrix protein scores are depicted next to the proteins with well-known immunogenicity. An asterisk indicates the average EpiMatrix protein score of all 100 pneumococcal proteins.](IAI.00098-19-f0001){#F1}

Predicted immunogenic HLA class II peptides induce T-cell proliferation in healthy donors. {#s2.2}
------------------------------------------------------------------------------------------

PBMCs of 21 healthy donors expressing at least one of the HLA-DRB1 alleles in the EpiMatrix system were stimulated with pools of synthetic peptides representing the selected most immunogenic regions per protein ([Table 2](#T2){ref-type="table"}). The amino acid ABC transporter (SP_1241) protein peptide pool was not able to induce proliferation in any of the 21 donors tested. All other protein peptide pools induced proliferation in up to 10 of the 21 donors ([Fig. 2A](#F2){ref-type="fig"} and [Table 3](#T3){ref-type="table"}). The highest stimulation indices (SIs) were found for PspA (SP_0117), BlpZ (SP_0546), putative ABC transporter ATP-binding protein exp8 (SP_1839), an uncharacterized protein (SP_0008), and a putative sortase (SP\_ 0468). Pneumolysin (SP_1923) showed the highest proliferative responses on average, coinciding with the highest percentage of responders ([Fig. 2A](#F2){ref-type="fig"} and [Table 3](#T3){ref-type="table"}).

![Immunogenicity screening of peptides using PBMCs from healthy adult donors. (A) Proliferation of healthy donor PBMCs after *in vitro* stimulation with peptide pools comprising the most immunogenic regions of the 20 selected proteins was measured. (B to D) In-depth analysis of potential immunogenic individual peptides of the protein PspA (B), BlpZ (C), or Ply (D) assessed in three donors responsive to respective peptide pools. Levels of cytokines produced present in the supernatants of donor PBMCs after single-peptide stimulation are illustrated using a unique colored line/symbol combination per donor/peptide combination, as indicated. (E) Different cytokine responses per donor/peptide stimulation are depicted with interconnecting lines for rapid visual evaluation but have no biological meaning. *y* axes indicate the stimulation index (fold proliferation over medium background) (A to D), and *x* axes depict tested peptide pools (A) or individual peptide locations within the protein (B to D), as indicated.](IAI.00098-19-f0002){#F2}

###### 

Overview of responders to peptide pools derived from the 20 selected pneumococcal proteins

  Gene name   Protein name                                             No. of responders[^*a*^](#T3F1){ref-type="table-fn"} after peptide pool stimulation (*n* = 21)   \% of responders
  ----------- -------------------------------------------------------- ------------------------------------------------------------------------------------------------ ------------------
  SP_0008     Uncharacterized protein                                  3/21                                                                                             14.3
  SP_0117     PspA                                                     5/21                                                                                             23.8
  SP_0468     Putative sortase                                         6/21                                                                                             28.6
  SP_0546     BlpZ                                                     7/21                                                                                             33.3
  SP_0641     Serine protease                                          4/21                                                                                             19.0
  SP_0667     Pneumococcal surface protein, putative                   1/21                                                                                             4.8
  SP_1072     DnaG                                                     2/21                                                                                             9.5
  SP_1241     Amino acid ABC transporter, amino acid-binding protein   0/21                                                                                             0.0
  SP_1434     ABC transporter, ATP-binding protein                     2/21                                                                                             9.5
  SP_1650     PsaA                                                     5/21                                                                                             23.8
  SP_1732     StkP                                                     1/21                                                                                             4.8
  SP_1839     Putative ABC transporter, ATP-binding protein Exp8       3/21                                                                                             14.3
  SP_1923     Ply                                                      10/21                                                                                            47.6
  SP_2048     Conserved hypothetical protein                           5/21                                                                                             23.8
  SP_2051     CglC                                                     1/21                                                                                             4.8
  SP_2136     PcpA                                                     3/21                                                                                             14.3
  SP_2201     CbpD                                                     2/21                                                                                             9.5
  SP_2204     RplI                                                     2/21                                                                                             9.5
  SP_2216     PcsB                                                     7/21                                                                                             33.3
  SPR_0907    PhtD                                                     5/21                                                                                             23.8

Stimulation index, ≥1.7.

Diverse T helper cell responses induced by individual immunogenic peptides. {#s2.3}
---------------------------------------------------------------------------

The immunogenicity per whole protein or peptide pool does not discriminate between the potential of single immunodominant epitopes. Therefore, responses at the single epitope level were investigated for PspA, BlpZ, and Ply using PBMCs from 3 out of the top 5 responders to corresponding peptide pools. Proliferation and cytokine secretion were measured after stimulation with individual peptides. Single peptides from PspA induced proliferation in one or more donors tested. PspA~225--242~ showed very strong stimulation of PBMCs of donor MB222 but did not show a response in the other two. In contrast, PspA~673--690~ induced proliferation in all three donors ([Fig. 2B](#F2){ref-type="fig"}). The overlapping BlpZ~30--47~ and BlpZ~40--57~ peptides showed proliferation in a single donor, with the more dominant response being to BlpZ~40--57~. The other peptides of BlpZ induced proliferation in 2/3 donors ([Fig. 2C](#F2){ref-type="fig"}). Two out of 10 single Ply peptides did not activate the PBMCs of any donor. The largely overlapping peptides Ply~405--422~ and Ply~408--425~ activated PBMCs of only a single donor. The strongest proliferative response was found after stimulation with Ply~236--259~ ([Fig. 2D](#F2){ref-type="fig"}).

T-cell activation after stimulation with single PspA, BlpZ, and Ply peptides was also evident by the detection of Th1 (gamma interferon \[IFN-γ\] and tumor necrosis factor alpha \[TNF-α\]), Th17 (IL-17A), and/or Th2 (IL-5 and IL-13) T helper type signature cytokines after 5 days in the culture supernatants from the tested donors ([Fig. 2E](#F2){ref-type="fig"}). No or limited amounts of IL-4 and IL-10 were detected. IFN-γ was found in responses to most BlpZ peptides, and only a single peptide induced TNF-α secretion. Conversely, all but one Ply peptide induced TNF-α, with only two peptides inducing IFN-γ. Th2 responses were most abundant against PspA and BlpZ peptides. Th17 responses were detected in response to 3/8 PspA, 4/10 BlpZ, and 3/7 Ply peptide stimulations ([Fig. 2E](#F2){ref-type="fig"}). Notably, single-peptide specificities could evoke the production of one or a combination of (two or three) of the Th1, Th2, and Th17 signature cytokines. For peptides tested in multiple donors, these patterns could be comparable (e.g., for PspA~673--690~ in donors MB204 and MB214) or dissimilar (e.g., for Ply~11--28~ in donors MB166 and MB209).

Isolation of a CD4^+^ T-cell clone to a predicted Ply epitope. {#s2.4}
--------------------------------------------------------------

To study if the reverse immunology strategy can identify truly processed and presented immunodominant CD4^+^ T-cell epitopes, we stimulated PBMCs from an HLA-DRB1\*15- and HLA-DRB1\*04-typed donor responding to the Ply peptide pool with a detoxified whole Ply and cloned the responding bulk culture by limiting dilution. We isolated a CD4^+^ T-cell clone (named 216-8E) showing strong proliferative capacity in response to a predicted Ply~235--252~ epitope and a weak or no response to neighboring peptides Ply~229--246~ and Ply~241--258~ ([Fig. 3A](#F3){ref-type="fig"}), providing proof of principle for the reverse immunology approach. The T-cell clone 216-8E recognizes the Ply~235--252~ epitope in the context of HLA-DR, as illustrated by reduced proliferation by adding anti-HLA-DR but not anti-HLA-DQ or anti-HLA-DP antibody (see Fig. S2A in the supplemental material). More specifically, as found after four-digit HLA typing of the donor's cells and the use of a panel of HLA-DR-matched and -mismatched antigen-presenting cells, 216-8E recognizes the peptide only in the context of HLA-DR\*15:02 (Fig. S2B). Functional characterization of 216-8E was performed using intracellular staining after exposure to autologous monocyte-derived dendritic cells (moDCs) loaded with whole pneumolysoid or heat-inactivated unencapsulated TIGR4 (TIGR4~ΔCPS~). The 216-8E T-cell clone produced TNF-α, IFN-γ, and IL-17A within the first 6 h in response to whole protein and heat-inactivated TIGR4~ΔCPS~ in three independent experiments ([Fig. 3B](#F3){ref-type="fig"} and [C](#F3){ref-type="fig"}). These data indicate a Th1/Th17 phenotype for this predicted Ply~235--252~ epitope-specific T-cell clone.

![Th1/Th17 dominated responses of CD4^+^ T-cell clone 216-8E to a predicted pneumolysin epitope. (A) The specificity of the isolated CD4^+^ T-cell clone 216-8E for Ply~235--252~ was assessed by measuring T-cell proliferation after stimulation with synthetic 12-mer overlapping Ply peptides. (B) Representative FACS plots of intracellular flow cytometric analysis of singlet live/CD3^+^/CD4^+^ 216-8E cells 6 h after exposure to autologous moDCs pulsed with whole pneumolysoid protein, heat-inactivated TIGR4~ΔCPS~, or medium (Mock). (C) Percentages of 216-8E cells stained positive for IFN-γ, TNF-α, IL-4, or IL-17A, using pooled data from three independent experiments.](IAI.00098-19-f0003){#F3}

DISCUSSION {#s3}
==========

High-throughput arrays have been used to screen for antibodies induced against pneumococcal proteins and have identified immunogenic proteins ([@B35], [@B36], [@B38]). In contrast, basic antigen tools for CD4^+^ T-cell immunogenicity screening are more complex due to dependence on MHC class II processing and presentation and limitations in human PBMC samples and were therefore lacking to date. We evaluated a bioinformatics screening tool, which has previously successfully been used to predict HLA-DRB1-restricted immunogenic consensus sequence pathogen-derived proteins for, e.g., Helicobacter pylori and hepatitis C virus ([@B45], [@B46]), to identify potentially T-cell immunogenic pneumococcal protein regions. Binding motifs for eight common HLA-DRB1 alleles were applied on primary sequences of 100 pneumococcal proteins of diverse subcellular localization. The cell-mediated arm of the immune system can recognize fragments of pathogen-derived proteins of any subcellular localization, as long as they are processed and presented in the context of MHC molecules on APC. Among the top 12 T-cell immunogenic proteins and 8 (pre)clinical vaccine candidates selected for further evaluation of T-cell recognition, 14 are known cell surface proteins, 2 are secreted proteins, 3 are intracellular, and 1 protein is of unknown subcellular localization.

Using synthetic peptides for *in vitro* stimulations, we evaluated the 2 to 5 most immunogenic regions of the top 12 immunogenic proteins and 8 known vaccine candidates in PBMCs of 21 healthy adult donors. These donors were likely previously exposed to pneumococcus by a single or multiple carriage episodes throughout life. Eight of the 20 protein peptide pools elicited proliferation in over 20% of the donors. Notably, five out of these eight proteins were (pre)clinical vaccine candidates. The vaccine candidates did not have a top EpiMatrix protein score; nonetheless, these proteins showed their T-cell immunogenic potential in this study, in addition to their already-known immunogenicity, albeit mainly based on humoral responses ([@B35], [@B43], [@B47], [@B50]). Only the peptide pool from the amino acid ABC transporter (SP_1241) was unable to induce proliferation in any of the donors despite its predicted immunogenicity. The lack of responses to peptides of this protein (or of any other protein) could be due to low protein expression by circulating strains, poor or no processing, presentation of the epitopes by APC, or lack of T-cell repertoire.

We characterized the cell proliferation and cytokine production at the level of single peptides within the immunogenic peptide pools of BlpZ (SP_0546), PspA (SP_0117), and Ply (SP_1923). PspA and Ply, but not BlpZ, have previously been described as immunogenic targets for CD4^+^ T cells ([@B39], [@B51]). We now show the immunogenicity of specific epitopes within these proteins. Interestingly, among the top 5 tested immunogenic regions of PspA, two immunogenic epitopes, PspA~593--610~ and PspA~673--690~, are within the C-terminal choline-binding module of PspA and contained the typical choline-binding repeat (CBR) consensus motifs, which are highly similar between different PspA clades and other pneumococcal choline-binding proteins (CBP) ([@B52]). Indeed, all repeats of PspA were predicted to be potential CD4^+^ T-cell epitopes, and similar CBR were predicted as immunogenic epitopes in SP_2136 (PcpA) but not among PcpA's top 5 most immunogenic regions (data not shown). The similarity of CBR within different CBP could explain the responsiveness of all three donors tested for this specific peptide ([Fig. 2B](#F2){ref-type="fig"}). The prevalence of hydrophobic and aromatic residues in CBR likely explains the presence of multiple HLA-DR binding motifs, which frequently prefer hydrophobic and aromatic residues at anchor sites. Whether the high prevalence of the CBR consensus motif in many CBP family members underlies T-cell cross-reactivity remains to be elucidated. The immunogenic PspA~185--204~ epitope identified in our study largely overlaps a previously predicted epitope, PspA~180--199~, which was suggested to be associated with protective IL-17A responses in mice ([@B43]). In our study, PspA~185--204~ was associated with a polyfunctional cytokine response, including IL-17A in PBMCs from a single human donor. Screening of additional donors is required to further assess the incidence and functionality of human responses to this epitope.

BlpZ was not previously associated with immunogenicity, as antibodies have not been detected against this protein yet ([@B35], [@B36], [@B38]). Here, we show the strong CD4^+^ T-cell immunogenic potential of this protein, with induction of IFN-γ, IL-17A, and IL-13 for different peptides. BlpZ is a bacterial immunity protein involved in the protection against bacteriocins, which are associated with virulent pneumococcus dispersed in biofilm ([@B48]). BlpZ-specific T-cell activation in response to pneumococcal dispersion might play an important role in clearance of pneumococcus from the nasopharynx. Domain 4 of Ply has been shown to induce Th17 responses in humans ([@B39]). Here, we predicted and evaluated an immunogenic region, Ply~405--425~, within this domain, and the peptide Ply~408--425~ in this region was shown to induce the production of IL-17A after exposure to PBMCs. In addition, we predicted and evaluated immunogenic peptides outside domain 4 of Ply. In particular, Ply~236--259~ was found to induce strong proliferation in one donor, and its immunogenicity was confirmed through isolation of a specific IL-17A-producing CD4^+^ T-cell clone.

We established that reverse immunology could predict *in vivo* processed and presented immunodominant epitopes by the isolation of the HLA-DR-restricted CD4^+^ T-cell clone from an HLA-DRB1\*04:03- and HLA-DRB1\*15:02-typed donor, specific for the above predicted Ply epitope. Interestingly, the T-cell clone appeared restricted by HLA-DRB1\*15:02 and was not able to recognize the peptide in the context of the closely related HLA-DRB1\*15:01 molecules, although this allele is predicted to bind the Ply epitope. Therefore, most likely our findings indicate that the polymorphism at position β86, lining the α-helix of the peptide-binding cleft, is relevant for recognition by the T-cell receptor of clone 216-8E but less likely so for differential binding of the epitope in HLA-DRB1\*15:01 and HLA-DRB1\*15:02. Functionally the CD4^+^ T-cell clone was characterized as having a mixed Th1 and Th17 phenotype by the production of IFN-γ, TNF-α, and IL-17A in response to whole protein. The potential immunodominance of this particular T cell within this donor was illustrated by the stimulation of the whole PBMC fraction of this donor, which showed strongest proliferation to this particular peptide ([Fig. 2D](#F2){ref-type="fig"}), which also induced production of IFN-γ, TNF-α, and IL-17A, in addition to the more limited production of IL-13 ([Fig. 2E](#F2){ref-type="fig"}). Ply is present in most pneumococcal clinical isolates and promotes mucosal inflammation, increasing bacterial spread and transmission ([@B53], [@B54]). APC can pick up Ply and activate CD4^+^ T-cell-mediated IL-17A production. The production of IL-17A in response to pneumococcal proteins has been implied to protect against carriage through the recruitment of neutrophils that phagocytose the bacterium. However, whether this particular CD4^+^ T-cell specificity could have a role *in vivo* against carriage in humans cannot be concluded from our data. *In vivo* studies are required to show local IL-17A production via activation of epitope-specific Th17 cells in response to Ply.

Previous work by Li et al. ranked the capacity of individual pneumococcal proteins to specifically elicit Th17 T-cell responses when presented in various protein pools ([@B44]). A small number of proteins (*n* = 8) with intermediate to high antigenicity scores in the Li et al. paper were also evaluated for potential T-cell immunogenicity (EpiMatrix protein score) in our study, six of which were further validated using peptide pools in proliferation assays. This small intersection of proteins and the divergent methodologies preclude a meaningful comparison of the ranking outcome between the two studies. Also, in principle, a protein could well elicit a strong Th17 type immune response based on one particular immunodominant epitope binding to a number of HLA class II alleles but could have a low EpiMatrix protein score if it lacks further sequences with HLA class II binding motifs. Nevertheless, the lymphoproliferative responsiveness found against all six intersecting and validated proteins in our study (SP_0641, SP_1072, SP_1434, SP_1839, SP_2136, and SP_2216; [Table 3](#T3){ref-type="table"}) confirmed that both approaches to identify T-cell immunogenic pneumococcal proteins yield common targets.

The EpiMatrix immunogenicity score of a protein is based on all potential epitopes binding the HLA-DR alleles included in the predictions. A high EpiMatrix score suggests a high probability of T-cell responses, but a low score does not exclude that a protein could evoke T-cell responses. As mentioned, among all potential epitopes a single peptide can be immunodominant. Therefore, we characterized the cell proliferation and cytokine production at the level of single peptides within the immunogenic peptide pools of BlpZ, PspA, and Ply, having divergent overall EpiMatrix protein scores. The breadth of the responses in donors differed from a single Ply peptide in MB209 to up to five PspA epitopes in MB222. Interestingly, a single-peptide specificity could also be associated with diverse Th type responses, as shown by the production of Th1, Th2, and Th17 signature cytokines after stimulation, even in a single donor. Moreover, different donors could respond similarly or differently against single-peptide specificities. Various pathogen and host factors may drive the primary selection and functional differentiation of CD4^+^ T-cell responses against a single epitope. These include pathogen virulence, duration of infection, and immunomodulatory properties of antigens involved, in combination with a donor's innate immune response, HLA background, and T-cell receptor repertoire ([@B55]). Further studies, including testing of more donors and response kinetics, are needed to determine if patterns exist in pneumococcal peptide- or protein-specific cytokines. The type of Th responses that can be induced to a protein/epitope may be crucial for its effectiveness *in vivo* and, hence, an important factor when developing targeted vaccine approaches.

A large diversity of HLA types, which all have various peptide binding motifs ([@B56]), is expressed by humans. The *in silico* prediction method used covered a wide range of HLA-DRB1 in four-digit typed alleles (e.g., HLA-DRB1\*01:01) but did not include the other HLA class II molecules, HLA-DRB3-, -4-, or -5-encoded HLA-DR molecules, HLA-DQ, and HLA-DP, which are also capable of presenting peptides. Through this limitation, the potential HLA class II-restricted epitope of the pneumococcal protein panel may have been underestimated. On the other hand, promiscuous HLA binding potential is a feature of many class II-restricted T-cell epitopes, and putative epitopes for HLA class II often tend to cluster in particular protein regions ([@B57]). In fact, our finding that the HLA-DRB1\*15:01-predicted Ply~235--252~ epitope was presented and recognized by a CD4^+^ T-cell clone in the context of HLA-DRB1\*15:02 underscores such promiscuity. As another limitation, we only included the top 5 immunogenic regions of the 20 selected proteins and may have missed T-cell epitopes that scored lower in this prediction model.

In conclusion, we investigated the T-cell immunogenic potential of previously studied and unstudied pneumococcal proteins, predicted T-cell immunogenic regions by *in silico* tools, and confirmed these predictions *in vitro*. Distinct Th-type responses were induced after single-peptide PBMC stimulation and T-cell clone activation. Reverse immunology, applying *in silico* predictions together with *in vitro* testing, proved a powerful semi-high-throughput approach to identify a series of immunogenic proteins and protein regions, useful to advance the development of immunomonitoring assays and targeted vaccine approaches.

MATERIALS AND METHODS {#s4}
=====================

Human blood and PBMC isolation. {#s4.1}
-------------------------------

Buffy coats were obtained from HLA class II (two-digit) typed healthy adult blood donors (Sanquin Blood Supply, Amsterdam, The Netherlands). All donors provided written informed consent in accordance with the local protocol for blood donations not for transfusion. The study was approved by the Medical Ethics Committee of Sanquin Blood Supply (Amsterdam, The Netherlands). PBMCs were isolated from buffy coats by Lymphoprep (Axis-Shield, Oslo, Norway) density gradient centrifugation. PBMCs were frozen in fetal calf serum (FCS; Greiner Bio-One, Kremsmünster, Austria) containing 10% dimethyl sulfoxide (DMSO; Sigma-Aldrich, Saint Louis, MO, USA) and stored at −135°C until use.

*In silico* T-cell immunogenicity predictions. {#s4.2}
----------------------------------------------

*In silico* immunogenicity predictions of whole pneumococcal proteins were performed using the EpiMatrix system (EpiVax, Providence, RI) ([@B58]). Protein sequences were from TIGR4 and R6 ([Table 1](#T1){ref-type="table"}). Sequences of 9-mer frames, with 8 overlapping amino acids, of the proteins were evaluated for binding motifs for a panel of eight common HLA-DRB1 alleles (DRB1\*01:01, DRB1\*03:01, DRB1\*04:01, DRB1\*07:01, DRB1\*08:01, DRB1\*11:01, DRB1\*13:01, and DRB1\*15:01), considered to represent additional family members and to cover over 98% of the human population ([@B59]). Each frame for each allele is scored (−3 to +3). EpiMatrix assessment scores (Z) above 1.64 indicate a significant chance of HLA-DR binding. The EpiMatrix protein score is the difference between the number of epitopes predicted and the number of T-cell epitopes expected to be found by chance in a protein of the same size. Proteins scoring above 20 were considered to have a significant overall immunogenic potential. Potential cross-reactivity of frames against the human genome was assessed using the JanusMatrix tool, which returns a score for a given peptide cluster or protein indicating the coverage within the human genome; Janus protein scores above 3.0 and peptide regions with an aggregated Janus cluster score of \>2 were considered potentially cross-reactive and, thus, nonimmunogenic ([@B57]). EpiBars, defined as 9-mer frames predicted to bind at least 4 of the 8 common HLA-DRB1 alleles, were further specified *in silico* for selected proteins. Protein regions of 15 to 25 amino acids with a high density of EpiMatrix assessment scores of \>1.64 were assigned an aggregated EpiMatrix cluster score. Cluster scores of \>10 were considered significant ([Fig. 1](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). For selected proteins, a maximum of 5 immunogenic regions with the highest EpiMatrix cluster scores were selected for peptide synthesis based on optimal EpiBar coverage. An overview of the reverse immunology process is depicted in Fig. S1 in the supplemental material.

Generation of synthetic peptides and protein and whole pneumococcal cell preparation. {#s4.3}
-------------------------------------------------------------------------------------

Peptides with a maximum length of 18 amino acids were chemically synthesized. For EpiBar-based immunogenic regions longer than 18 amino acids, two partially overlapping peptides were designed (Pepscan, Lelystad, The Netherlands). In total, 160 synthetic peptides were synthesized, representing 99 potential immunogenic regions. Peptides were dissolved in DMSO at a stock concentration of 1 mM per peptide. Pools for each protein were assembled, varying from 4 to 12 peptides per pool. PlyD1, a genetically detoxified pneumolysin (T65C, G293C, and C428A), was kindly provided by M. Ochs (Sanofi-Pasteur, Swiftwater, PA, USA). TIGR4~ΔCPS~ was kindly provided by M. de Jonge (Radboud University Medical Center, Nijmegen, The Netherlands) ([@B60]) and was cultured up to an optical density of 0.6. An inactivated whole-cell preparation was prepared by 1 h of heat inactivation of the biomass at 56°C.

HLA typing and cell lines. {#s4.4}
--------------------------

Four-digit molecular typing for HLA class II alleles of blood donors was performed based on the sequence-specific oligonucleotide PCR technique in combination with Luminex using commercial reagents on PBMC-derived DNA at the Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands (H. Otten and E. Spiering). Four-digit HLA-typed Epstein-Barr virus-transformed B-cell lines (B-LCL) for MHC restriction analysis were kindly provided by F. Claas (Leiden University Medical Centre).

Immunogenicity screening of predicted peptides. {#s4.5}
-----------------------------------------------

PBMCs from donors, selected to express at least 1 of the 8 common HLA-DRB1 alleles in the EpiMatrix system (based on their two-digit HLA-DRB1 typing), were stimulated in AIM-V (Gibco, Thermo Fisher Scientific, Waltham, MA, USA), supplemented with 2% human AB serum (Sigma-Aldrich) (referred to as complete AIM-V), in 96-well U-bottom plates at a concentration of 1.5 × 10^5^ cells/well in the presence of individual or pooled peptides (at 1 μM per peptide) or medium as a negative control. Stimulations were performed in quadruplicate wells and incubated for 5 days at 37°C with 5% CO~2~. Here, supernatant was harvested, pooled for quadruplicate stimulations, and stored at −20°C, and cell proliferation was determined.

Cell proliferation. {#s4.6}
-------------------

Cell proliferation was determined after 5 days of *in vitro* stimulation by adding tritium thymidine (18 kBq/well) to the 96-well plates for overnight incubation at 37°C with 5% CO~2~ to be incorporated in the cellular DNA with every cell division. Cells were then harvested on a filter, and incorporated label was determined as counts per minute (cpm) using a MicroBeta counter (Perkin Elmer). Stimulation indices (SIs) were calculated by dividing the mean cpm of the quadruplicate stimulated wells by the mean cpm of the quadruplicate medium control wells. SIs of \>1.7 were considered positive, and results are shown as mean SIs per group with standard deviations.

Cytokine responses. {#s4.7}
-------------------

Concentrations of IL-2, IL-4, IL-5, IL-10, IL-13, IL-17, TNF-α, and IFN-γ were measured in pooled cell culture supernatants using a human cytokine kit (Merck-Millipore, Burlington, MA, USA) and multiplex technology according to instructions of the manufacturer. Samples were measured and data were analyzed with Bio-Plex200 and Bio-Plex Manager 5.0 software (Bio-Rad Laboratories).

Cloning of Ply-specific CD4^+^ T cells. {#s4.8}
---------------------------------------

PBMCs of donor responding to the Ply peptide pool were stimulated with PlyD1 at 1 μg/ml in complete AIM-V at 37°C in 5% CO~2~. After 7 days of expansion, stimulated T cells were diluted to nearly single cells and cultured in the presence of gamma-irradiated feeder cells at 1.5 × 10^5^ PBMC/well and phytohemagglutinin at 1 μg/ml in 96-well plates at 37°C in 5% CO~2~ for 2 to 3 weeks. Expanding T-cell cultures from plates with \<36% cell outgrowth were considered potentially clonal and were evaluated for reactivity to whole protein stimulation with autologous APC before assessing the epitope specificity through peptide stimulations.

Restriction analysis of CD4^+^ T-cell clone. {#s4.9}
--------------------------------------------

MHC restriction of Ply~235--252~-specific CD4^+^ T-cell clone 216-8E was assessed by measuring proliferation after whole protein stimulation using autologous or HLA-typed B-LCL as APCs. APCs were mock pulsed or pulsed with PlyD1 at 1 μg/ml overnight at 37°C in 5% CO~2~, washed, fixed using 0.25% paraformaldehyde solution for 10 min at room temperature, and washed with 0.2 M glycine solution. Anti-HLA-DR (B8.11-2; in-house), anti-HLA-DQ (SPV-L3; in-house), or anti-HLA-DP (B7/21; Leinco Technologies, Fenton, MO, USA) blocking antibody was used to confirm the restricting element of clone 216-8E. T-cell receptor Vα and Vβ sequencing confirmed clonality of Ply~235--252~-specific CD4^+^ T-cell clone 216-8E.

Generation of moDCs. {#s4.10}
--------------------

PBMCs were thawed, plated at 40 × 10^6^ cells per T75 flask in Iscove's modified defined medium (IMDM; Gibco, Life Technologies) containing 1% FCS and 1% penicillin-streptomycin (Gibco, Life Technologies), and incubated at 37°C in 5% CO~2~. Monocytes were isolated using plastic adherence and cultured as follows. Nonadherent cells were removed after 2 h, and adherent cells were washed once with phosphate-buffered saline. IMDM containing 1% FCS, 1% penicillin-streptomycin, IL-4 (500 U/ml; PeproTech, Rocky Hill, NJ, USA), and granulocyte-macrophage colony-stimulating factor (500 U/ml; PeproTech) was added to adherent cells. Monocytes were differentiated into monocyte-derived dendritic cells (moDCs) for 5 days.

Flow cytometry. {#s4.11}
---------------

Flow cytometric analysis was used to determine intracellular cytokines produced by the CD4^+^ T-cell clone 216-8E after 6 or 26 h of exposure to moDCs loaded with heat-inactivated TIGR4~ΔCPS~ (10^7^ culture-forming units/ml), PlyD1 (1 μg/ml), or no antigen as a control. In the last 4 h of stimulation, brefeldin A (BD Bioscience, San Jose, CA, USA) was added to capture intracellular cytokines. Cells were stained using fixable live/dead dye (ZombieNIR; BioLegend, San Diego, CA, USA) for 10 min at room temperature. After washing, surface proteins were stained using anti-human CD3 (SK7), CD4 (OKT4), and CD8 (SK1; all from BioLegend) antibodies for 20 min at 4°C. Cells were fixed and permeabilized using a fixation/permeabilization kit (eBioscience, San Diego, CA, USA) according to the manufacturer's protocol, followed by staining with anti-human IFN-γ (B27), TNF-α (Mab11), IL-17A (BL168) (all from BioLegend), and IL-4 (MP4-25D2; BD, Franklin Lakes, NJ, USA). Cells were measured using the fluorescence-activated cell sorter LSRFortessa X-20 (BD).

Data availability. {#s4.12}
------------------

The data generated or analyzed in this study are available from the corresponding author on reasonable request.
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###### Supplemental file 1
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Supplemental material for this article may be found at <https://doi.org/10.1128/IAI.00098-19>.
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